

Subependymal giant cell astrocytoma (SEGA), unrelated to tuberous sclerosis, NTRK-positive

Veronica Parrella, Jacopo Ferro, Chiara Trambaiolo Antonelli, Gabriele Gaggero 

Pathology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy




Figure 1. Photomicrograph (haematoxylin-eosin, 40x), showing a neoplasm consisting of epithelioid/ganglioid cells with a large cytoplasm and prominent nucleolus




Figure 2. Immunohistochemistry showing positivity in the neoplastic cells for NTRK

An 11-year-old child presented with hydrocephalus-related symptoms. MR demonstrated, in the post T1-weighted image, an enhancing intraventricular mass in the frontal horn of the right lateral ventricle. The patient underwent neurosurgery, and histology showed it to be a neoplasm with compact architecture, high cellularity, large cells with eosinophilic cytoplasm, in the absence of mitosis and/or vascular proliferation and/or necrosis (fig. 1). Immunohistochemistry revealed positivity for GFAP and S-100. The diagnosis was SEGA – a rare glial neoplasm typically located in the wall of the lateral ventricles and usually associated with tuberous sclerosis (TS), an autosomal dominant syndrome harbouring mutations in the *TSC1* and *TSC2* genes, although cases unrelated to TS are reported. Our case fits into this context of rarity: indeed, the patient was referred for genetic counselling after histological diagnosis, but no alteration in tuberous sclerosis-related genes was found. Although WHO-CNS2016 and WHO-CNS2021c-classifications have introduced real "revolutions" in the morpho-molecular aspects of most primary brain neoplasms, SEGA has not substantially changed its classification, always maintaining its

features (grade 1 according to WHO-CNS2021), and constituting one of the longest-lived entities of all CNS tumours [1]. Probably because of the rarity of SEGA – compared to neoplasms with extremely higher incidence, prevalence and mortality – histologic expression of predictive targets in SEGAs has not been studied to date. Our immunohistochemistry results were: NTRK+ (fig. 2), ALK–, PDL1–, PD1–, CTLA4–. To date, SEGA therapy is limited to m-TOR inhibitors, such as rapamycin [2], and therefore the immunohistochemical NTRK-positivity could potentially broaden the ever-expanding landscape of tumours that are treatable with TRK-inhibitors, whereas our results suggest no correlation with immunocheckpoint expression.

References

1. WHO Classification of Tumours Editorial Board. Central nervous system tumours. WHO classification of tumours series, 5th ed.; vol. 6. International Agency for Research on Cancer, Lyon 2021.
2. Ebrahimi-Fakhari D, Franz DN. Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA). *Expert Opin Pharmacother.* 2020; 21(11): 1329–1336, doi: 10.1080/14656566.2020.1751124, indexed in Pubmed: 32338549.

How to cite:

Parrella V, Ferro J, Trambaiolo Antonelli C, Gaggero G. *Subependymal giant cell astrocytoma (SEGA), unrelated to tuberous sclerosis, NTRK-positive.* *NOWOTWORY J Oncol* 2024; 74: 72.

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.